Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19346592 | 1.00 | SLC6A2 (0.39) | SLC6A2SLC6A4MAOBHTR2AGBA1 | |
| SCHEMBL29881279 | 1.00 | SLC6A2 (0.39) | SLC6A2SLC6A4MAOBHTR2AGBA1 | |
| SCHEMBL19346688 | 0.86 | SLC6A2 (0.51) | SLC6A2SLC6A4IDO1TDO2CYP3A4 | |
| SCHEMBL20838359 | 0.86 | SLC6A2 (0.51) | SLC6A2SLC6A4IDO1TDO2CYP3A4 | |
| SCHEMBL19346591 | 0.86 | SLC6A2 (0.51) | SLC6A2SLC6A4IDO1TDO2CYP3A4 | |
| SCHEMBL19329845 | 0.82 | SLC6A4 (0.46) | SLC6A2SLC6A4HTR2ACYP3A4CYP2D6 | |
| SCHEMBL19346524 | 0.82 | SLC6A4 (0.46) | SLC6A2SLC6A4HTR2ACYP3A4CYP2D6 | |
| SCHEMBL20838397 | 0.82 | OPRM1 (0.42) | SLC6A2SLC6A4MAOBGBA1CYP3A4 | |
| SCHEMBL20838427 | 0.82 | SLC6A2 (0.42) | SLC6A2SLC6A4PNMTGABBR2GABBR1 | |
| SCHEMBL20838426 | 0.82 | SLC6A2 (0.42) | SLC6A2SLC6A4PNMTGABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453677-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | NOVARTIS AG (CH) | 2022-09-27 | — | — | US | disclosed |
| EP-3426656-B1 | TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2021-05-12 | — | — | EP | disclosed |
| US-10858366-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | NOVARTIS AG (CH) | 2020-12-08 | — | — | US | disclosed |
| US-20200347072-A1 | Tricyclic Compounds Useful to Treat Orthomyxovirus Infections | NOVARTIS AG (CH) | 2020-11-05 | — | — | US | disclosed |
| US-20190092780-A1 | TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858366-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | ZC3HAV1, OTC, THOP1 | SLC6A2 3183/4885SLC6A4 3749/4885MAOB 1218/4885 |
| US-20200347072-A1 | Tricyclic Compounds Useful to Treat Orthomyxovirus Infections | ZC3HAV1, OTC, THOP1 | SLC6A2 3183/4885SLC6A4 3714/4885MAOB 1023/4885 |
| US-11453677-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | ZC3HAV1, OTC, THOP1 | SLC6A2 3183/4885SLC6A4 3714/4885MAOB 1023/4885 |
| US-20190092780-A1 | TRICYCLIC COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | ZC3HAV1, OTC, THOP1 | SLC6A2 3183/4885SLC6A4 3749/4885MAOB 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.